智通财经APP讯，康哲药业(00867)发布公告，于2026年2月12日，本集团通过本公司附属公司与Teikoku Pharma USA, Inc.(TPU, 为日本Teikoku Seiyaku Co., Ltd(TSC，帝国制药)的附属公司，以下合称合作方) 就Lidoderm利多卡因凝胶贴膏(产品)签订独家经销协议(协议)。 （原标题：康哲药业(00867)：签订原研药Lidoderm®利多卡因凝胶贴膏独家经销协议） TPU是日本TSC的子公司，在疼痛管理、中枢神经系统疾病和皮肤病学等多个治疗领域开发创新产品。 TSC历史悠久，可追溯至1848年由赤泽家族创立的公司，总部位于日本香川县，并在东京和大坂设有办 事处。TSC的能力涵盖研发、临床、监管、制造和商业。 TSC率先研发出经皮给药的药物，作为全球最 大的水凝胶贴剂制造商和药物递送公司之一，TSC目前生产超过200种处方药和非处方药产品，产品销 往50多个国家。TSC还生产口服和其他外用制剂，其治疗重点是疼痛管理和皮肤病学。 本集团持续深化差异化产品布局。疼痛管理及带状疱疹后遗神经痛专科治疗市场需求显著，而现有口服 药物在局部靶向性与长期用药安全性方 ...

Group 1 - 康哲药业 has signed an exclusive distribution agreement with Teikoku Pharma USA, Inc. for the Lidoderm product, granting the company exclusive rights in mainland China for ten years starting from the first commercial sale [1] - Lidoderm is a lidocaine patch approved by the FDA in 1999 for treating postherpetic neuralgia (PHN), with clinical studies showing about 25% to 33% of patients experiencing at least 50% pain relief within 4 to 12 weeks [2] - The prevalence of PHN is significant, with estimates suggesting that approximately 4 million patients in China may be affected, particularly among older populations [3] Group 2 - Teikoku Pharma USA, Inc. is a subsidiary of Teikoku Seiyaku Co., Ltd., which has a long history in developing innovative products for pain management and other therapeutic areas [4] - The introduction of Lidoderm enhances 康哲药业's product portfolio and is expected to synergize with existing products, expanding market reach and driving growth [5] - The company aims to leverage new retail and multi-channel marketing strategies to create a comprehensive commercial ecosystem, enhancing both hospital and outpatient market penetration [5]

Group 1 - The company signed an exclusive distribution agreement for Lidoderm® with Teikoku Pharma USA, Inc., granting exclusive rights in mainland China for ten years starting from the first commercial sale [1] - Lidoderm® is a lidocaine patch approved by the FDA in 1999 for treating postherpetic neuralgia (PHN), with clinical studies showing about 25% to 33% of patients experiencing at least 50% pain relief within 4 to 12 weeks [2] - The product is recognized in clinical guidelines for its effectiveness and safety in treating PHN and other neuropathic pain conditions, such as diabetic peripheral neuropathic pain [2][3] Group 2 - PHN is defined as pain persisting for one month or more after the healing of herpes zoster rash, with a significant prevalence among older adults, particularly those aged 60 and above [3] - The company aims to enhance its product portfolio with Lidoderm®, leveraging its brand advantages and existing marketing channels to create synergies and expand into new retail models [5] - The collaboration is expected to positively impact the company's operational performance and align with the interests of its shareholders [5] Group 3 - Teikoku Pharma USA, Inc. is a subsidiary of Teikoku Seiyaku Co., Ltd., which has a long history in developing innovative products in pain management and dermatology, producing over 200 prescription and over-the-counter products [4] - The demand for pain management solutions, particularly for PHN, is significant, and topical patches are well-recognized in the Chinese market for their direct and convenient application [4]